NewsBenzinga아고맙 테라퓨틱스, 중증 크론병 환자 대상 온투니세르티브 평가 2a상 STENOVA 시험의 48주 OLE 결과 발표···최대 60주 치료 기간 동안 안전성 및 내약성 유지, 연간 FSCD 관련 사건 발생률 3%로 낮은 수준 아고맙 테라퓨틱스, 중증 크론병 환자 대상 온투니세르티브 평가 2a상 STENOVA 시험의 48주 OLE 결과 발표···최대 60주 치료 기간 동안 안전성 및 내약성 유지, 연간 FSCD 관련 사건 발생률 3%로 낮은 수준 Benzinga 2026.10.01 10:38 (GMT+0) Open on Benzinga Other news Airbnb Co-Founder Joe Gebbia Says He Modernized Federal Retirement System In 6 Months for $1.5 Million After Contractors Spent $100 Million NVIDIA's Jensen Huang Crisis Threatens to Rewrite the Rules of the AI Boom Mondelez's Multi-Million Portfolio Shift: Unloads French Bakery and Cereal Bars Business Ur-Energy Begins Fieldwork For Baseline Studies At Its Lost Solider Project; Will Take Construction Decision For Potential Third Mine After Technical Report Azora Therapeutics Files Prospectus For $250M Mixed Securities Shelf; May Sell Up To $20M Of Stock Under Sales Agreement With Jefferies Chuck Schumer Slams Trump Over Plan to Cut Food Stamps for 6 Million Americans: 'Empty Dinner Plates Across America'
Airbnb Co-Founder Joe Gebbia Says He Modernized Federal Retirement System In 6 Months for $1.5 Million After Contractors Spent $100 Million
Ur-Energy Begins Fieldwork For Baseline Studies At Its Lost Solider Project; Will Take Construction Decision For Potential Third Mine After Technical Report
Azora Therapeutics Files Prospectus For $250M Mixed Securities Shelf; May Sell Up To $20M Of Stock Under Sales Agreement With Jefferies
Chuck Schumer Slams Trump Over Plan to Cut Food Stamps for 6 Million Americans: 'Empty Dinner Plates Across America'